



CASE DB19 DIV3

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF

Art Unit: 1626

GU ET AL.

APPLICATION NO: 10/717,287

Examiner: STOCKTON, LAURA

FILED: November 19, 2003

FOR: NOVEL INHIBITORS OF IMPDH ENZYME

Assistant Commissioner for Patents
Alexandria, VA 22313-1450

FEE LETTER

Sir:

Enclosed herewith is a Terminal Disclaimer in the above-identified application.

The Commissioner is hereby authorized to charge the \$110 fee under 37 CFR §1.20(d) and any additional fees that may be required to Deposit Account No. 19-3880 in the name of Bristol-Myers Squibb Company. An additional copy of this paper is here enclosed.

Respectfully submitted,

Bristol-Myers Squibb Company
Patent Department
P.O. Box 4000
Princeton, NJ 08543-4000
(609) 252-5323
Date: May 9, 2005


Laurelee A. Duncan
Attorney for Applicants
Reg. No. 44,096



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF

Art Unit: 1626

GU ET AL.

Examiner: STOCKTON, LAURA

APPLICATION NO: 10/717,287

FILED: November 19, 2003

FOR: NOVEL INHIBITORS OF IMPDH ENZYME

Assistant Commissioner for Patents
Alexandria, VA 22313-1450

TERMINAL DISCLAIMER

Sir:

Bristol-Myers Squibb Company, a Delaware corporation, having a place of business at Lawrenceville-Princeton Road, Princeton, NJ 08543-4000, represents that it is the assignee and owner of the entire interest in the above-identified divisional application by virtue of an assignment to the parent application which was recorded in the United States Patent and Trademark Office on October 27, 1999 at Reel/Frame 010348/0101.

Bristol-Myers Squibb Company hereby disclaims, except as provided below, the terminal part of the statutory term of any patent granted on the above-identified application which would extend beyond the expiration date of the full statutory term defined in 35 USC §154-156 and §173, as presently shortened by any terminal disclaimer, of prior Patent No. 6,624,184 issued September 23, 2003, also assigned to Bristol-Myers Squibb Company by virtue of the assignment mentioned above.

Bristol-Myers Squibb Company hereby agrees that any patent granted on the above-identified application shall be enforceable only for and during such period that it and prior Patent No. 6,624,184 are commonly owned. This agreement runs with any patent granted on the above-identified application and is binding upon the grantee, its successors or assigns.

In making the above disclaimer, Bristol-Myers Squibb Company does not disclaim the terminal part of any patent granted on the above-identified application that would extend to the expiration date of the full statutory term as defined in 35 USC §154-156 and §173 of prior Patent No. 6,624,184, as presently shortened by any terminal disclaimer, in the event that it later: expires for failure to pay a maintenance fee, is held unenforceable, is found invalid by a court of competent jurisdiction, is statutorily disclaimed in whole or terminally disclaimed under 37 CFR §1.321, has all claims cancelled by a reexamination certificate, is reissued, or is in any manner terminated prior to the expiration of its full statutory term as presently shortened by any terminal disclaimer.

A terminal disclaimer fee under 37 CFR §1.20(d) is included.

Signed this 9th day of May, 2005 by the undersigned attorney of record.

Bristol-Myers Squibb Company
Patent Department
P.O. Box 4000
Princeton, NJ 08543-4000
(609) 252-5323


Laurelee A. Duncan
Attorney for Applicants
Reg. No. 44,096